Actuate Therapeutics Targets $200M+ Pediatric Voucher with Oral Elraglusib and RAS Trials
Actuate Therapeutics reported complete responses in pediatric Ewing sarcoma and neuroblastoma, qualifying elraglusib for Rare Pediatric Disease Designation and a potential Priority Review Voucher worth $150–200M upon FDA approval. The company’s oral elraglusib shows ~51% bioavailability and it’s launching RAS inhibitor combination trials in H2 2026.
1. Pediatric Trial Results and PRV Eligibility
Actuate reported two complete responses in relapsed/refractory metastatic Ewing sarcoma and one in neuroblastoma among 40 pediatric patients, securing Rare Pediatric Disease Designation for both indications. Approval for either could yield a Priority Review Voucher valued at $150–200M to fund further development.
2. Oral Formulation Pharmacokinetics
The oral formulation completed a Phase 1 study in healthy volunteers with ~51% bioavailability relative to IV when dosed with food, exhibiting dose-proportional pharmacokinetics and no unexpected safety signals. A Phase 1 dose-escalation trial in advanced cancer patients is planned for later in 2026.
3. RAS Combination Initiative
Actuate has launched preclinical studies combining elraglusib with RAS(ON) inhibitors such as daraxonrasib and elironrasib to tackle adaptive resistance in KRAS-mutant pancreatic, colorectal and lung cancers. Initial combination data are expected in the second half of 2026.
4. Strategic Implications and Funding Outlook
Monetizing a Priority Review Voucher could provide transformative non-dilutive capital to support late-stage trials, oral formulation advancement and strategic partnerships. This funding option positions elraglusib as a backbone therapy in both rare pediatric cancers and larger RAS-driven solid tumor markets.